CMTM6 review highlights roles in tumor progression, immune evasion, and therapeutic targeting potential

The chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing (CMTM) family plays a crucial role in cellular processes, with CMTM6 exhibiting characteristics bridging classical chemokines and tetraspanins. While expressed in normal immune, reproductive, and nervous tissues, its expression is frequently and significantly upregulated across a broad spectrum of tumors, including lung, liver, and gastrointestinal carcinomas. This upregulation drives tumor progression by inhibiting immune responses, facilitating immune evasion, and inducing epithelial-mesenchymal transition (EMT), directly impacting patient prognosis. A comprehensive synthesis of CMTM6's diverse molecular functions and clinical implications is essential to guide novel therapeutic strategies.

This systematic review comprehensively summarized existing literature on CMTM6's molecular functions, mechanisms of action, and disease-related expression patterns. The authors aimed to provide a holistic overview of its role in disease pathogenesis and evaluate its clinical translational applications. The review synthesized findings from numerous studies to identify common themes and specific pathways through which CMTM6 influences tumor biology, ultimately seeking to guide the development of targeted therapeutic strategies.

The review consistently identified CMTM6's significant and multifaceted role in promoting tumor proliferation, invasion, and metastasis across a broad spectrum of cancer types. It was found to actively contribute to tumor progression by inhibiting host immune responses, thereby facilitating immune evasion. Furthermore, CMTM6 consistently induces epithelial-mesenchymal transition (EMT), a critical cellular process that enables cancer cells to acquire migratory and invasive properties, crucial for metastasis. These combined actions collectively influence patient prognosis and survival outcomes, with high CMTM6 expression frequently correlating with poorer clinical outcomes. The review underscores CMTM6's dual nature, acting as both a critical regulator in normal physiology and a potent oncogenic driver when dysregulated.

The review highlights that CMTM6 consistently contributes to tumor proliferation, invasion, and metastasis by inhibiting immune responses and inducing epithelial-mesenchymal transition.